- Home
- EOD vs TLSA Comparison
EOD vs TLSA Comparison
Compare EOD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- TLSA
- Stock Information
- Founded
- EOD 2007
- TLSA 2013
- Country
- EOD United States
- TLSA United Kingdom
- Employees
- EOD N/A
- TLSA N/A
- Industry
- EOD Investment Managers
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- EOD Finance
- TLSA Health Care
- Exchange
- EOD Nasdaq
- TLSA Nasdaq
- Market Cap
- EOD 245.0M
- TLSA 240.0M
- IPO Year
- EOD N/A
- TLSA 2000
- Fundamental
- Price
- EOD $5.77
- TLSA $1.89
- Analyst Decision
- EOD
- TLSA
- Analyst Count
- EOD 0
- TLSA 0
- Target Price
- EOD N/A
- TLSA N/A
- AVG Volume (30 Days)
- EOD 118.1K
- TLSA 342.2K
- Earning Date
- EOD 01-01-0001
- TLSA 05-06-2025
- Dividend Yield
- EOD 9.28%
- TLSA N/A
- EPS Growth
- EOD N/A
- TLSA N/A
- EPS
- EOD N/A
- TLSA N/A
- Revenue
- EOD N/A
- TLSA N/A
- Revenue This Year
- EOD N/A
- TLSA N/A
- Revenue Next Year
- EOD N/A
- TLSA N/A
- P/E Ratio
- EOD N/A
- TLSA N/A
- Revenue Growth
- EOD N/A
- TLSA N/A
- 52 Week Low
- EOD $3.73
- TLSA $0.63
- 52 Week High
- EOD $4.71
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- EOD 59.47
- TLSA 44.68
- Support Level
- EOD $5.65
- TLSA $1.81
- Resistance Level
- EOD $5.74
- TLSA $2.04
- Average True Range (ATR)
- EOD 0.07
- TLSA 0.17
- MACD
- EOD 0.00
- TLSA -0.03
- Stochastic Oscillator
- EOD 86.36
- TLSA 15.38
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.